Sci. Signal., 13 April 2010
Cancer Therapy Arsenic on the Fingers
Paula A. Kiberstis
Science, AAAS, Washington, DC 20005, USA
Arsenic, an ancient drug used in traditional Chinese medicine, has attracted wide interest because it has therapeutic activity in patients with acute promyelocytic leukemia (APL). The drug acts by promoting degradation of an oncogenic protein, PML-RAR, a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor , which is found specifically in APL cells and helps drive their growth. Zhang et al. (see the Perspective by Kogan) now explain how arsenic initiates the molecular events leading to PML-RAR degradation. Arsenic was found to bind directly to cysteine residues within zinc finger domains of PML. Arsenic binding then induced oligomerization of PML, which in turn enhanced its association with an enzyme that helps catalyze SUMOylation, a posttranslational modification that can target proteins for degradation.
X.-W. Zhang, X.-J. Yan, Z.-R. Zhou, F.-F. Yang, Z.-Y. Wu, H.-B. Sun, W.-X. Liang, A.-X. Song, V. Lallemand-Breitenbach, M. Jeanne, Q.-Y. Zhang, H.-Y. Yang, Q.-H. Huang, G.-B. Zhou, J.-H. Tong, Y. Zhang, J.-H. Wu, H.-Y. Hu, H. de Thé, S.-J. Chen, Z. Chen, Arsenic trioxide controls the fate of the PML-RAR oncoprotein by directly binding PML. Science 328, 240–243 (2010). [Abstract] [Full Text]
Citation: P. A. Kiberstis, Arsenic on the Fingers. Sci. Signal. 3, ec113 (2010).
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882